<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIMANTADINE</span><br/>(ri-man'ta-deen)<br/><span class="topboxtradename">Flumadine<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Amantidine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg tablets; 50 mg/5 mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>Antiviral agent for treatment and prophylaxis of influenza A infections. Thought to exert an inhibitory effect early in the
         viral replication cycle, probably by interfering with the viral uncoating procedure of the influenza A virus.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits synthesis of both viral RNA and viral protein, thus preventing or interrupting influenza A infections.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of influenza A in adults and prophylaxis of influenza A in children.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rimantadine and amantadine; pregnancy (category C), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of seizures. Safety and efficacy in treatment of symptomatic influenza infection in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prophylaxis of Influenza A</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;<i>10 y</i>, 100 mg b.i.d., reduce to 100 mg daily in older adults or patients with liver disease<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10 y, 5 mg/kg once daily (max: 150 mg/d)<br/><br/><span class="indicationtitle">Treatment of Influenza A</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg b.i.d., reduce to 100 mg daily in older adults or patients with liver disease, initiate as soon as possible and preferably
               within 48 h of onset of symptoms and continue for about 7 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Nervousness, dizziness, headache, sleep disturbances, fatigue or malaise, drowsiness, anticholinergic effects. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, dyspepsia, dry mouth, anorexia, abdominal pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> Serum levels 3.24.3 h. <span class="typehead">Distribution:</span> Concentrates in respiratory secretions. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> Excreted by kidneys. <span class="typehead">Half-Life:</span> 2036 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for seizure activity in patients with a history of seizures. Seizures are an indication to discontinue the
            drug.
         </li>
<li>Monitor cardiac, respiratory, and neurologic status while on drug. Report palpitations, hypertension, dyspnea, or pedal edema.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report bothersome adverse effects to physician; especially hallucinations, palpitations, difficulty breathing, and swelling
            of legs.
         </li>
<li>Use caution with hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>